Stophairlossnow

National hair expert Dr. Alan Bauman predicts the NeoGraft hair transplant will revolutionize the industry - and he's helping to train other qualified hair restoration surgeons in how to use it.

April 2010

Noted hair transplant surgeon Alan J. Bauman, M.D. was the first physician to demonstrate NeoGraft, the minimally-invasive hair transplant device, at the International Society of Hair Restoration Surgery’s (ISHRS) Annual Live Surgery Workshop in Orlando this month. One of the most experienced NeoGraft surgeons worldwide, Dr. Bauman lectured about the device as well as demonstrated its use on a live patient for the over 100 physicians, assistants and others who were in attendance.

Dr. Alan Bauman demonstrates NeoGraft FUE Hair Transplant at ISHRS Orlando Live Surgery Workshop, April 2010The April 2010 Orlando workshop was the first live surgery demonstration of the NeoGraft device at an official International Society of Hair Restoration Surgery-sponsored event since the device made its debut in North America in 2008.

“NeoGraft has been an incredible breakthrough that benefits both hair transplant patients and physicians,” said Dr. Bauman, who is certified by the American and International Board of Hair Restoration Surgery and one of the first U.S. doctors to use the device. “The ISHRS workshop was a great opportunity to educate more hair transplant doctors about this important new tool in the battle against baldness. NeoGraft delivers what savvy hair loss patients are demanding—a less invasive hair transplant that heals quickly and comfortably, and leaves no linear scar.”

During the live surgery teaching demonstration, Dr. Bauman and his assistants harvested a total of 357 consecutive individual ‘follicular-unit’ grafts in just one hour using NeoGraft, with a very low graft transection rate of 2.2-percent--illustrating the device’s efficiency and accuracy.

“This year’s lectures and surgeries certainly did not disappoint,” said Dr. Edwin Epstein, president of the ISHRS and workshop attendee. “The ISHRS Annual Orlando Live Surgery Workshop is the foremost physician training event in the field bringing together physicians of all skill levels from novice to advanced to share the latest information on hair loss and its treatment.”

What is Neograft/Fue

The FDA-cleared NeoGraft device helps automate the surgical removal of individual hair follicles and follicular-units one at a time, eliminating the need for doctors to remove a large strip from the back of the scalp (a procedure known as a linear-harvest Follicular Unit Hair Transplant or STRIP FUT).

The targeted removal of individual hair follicles, known as "Follicular-Unit Extraction" or FUE, is a minimally-invasive microsurgical procedure that has been available for several years, but until now has been too time-consuming or too costly for many patients.

"NeoGraft is an exciting new breakthrough because it allows for the same artistic ‘follicle-by-follicle’ natural hair transplant results, but now with the advantage of the no-scalpel/no-stitch FUE harvest technique," Dr. Bauman said. “NeoGraft is a huge step forward in FUE efficiency and accuracy.”

Complete hair transplant article

Categories: Hair Loss, Hair Loss Treatment, Hair Transplant

Alopecia (Hair Loss) Therapy Area Pipeline Report contains detailed information on the alopecia (hair loss) drug pipeline.

This report provides insight into the pipeline status of alopecia (hair loss) drugs by company and by stage as well as a summary of the latest news and developments in this area.

Scope of the report:

Each Therapy Area Pipeline Report provides the user with real detail on drug pipelines, by company and by stage, for each specific therapy area. The latest news, by company, also ensures that each report is fresh and up-to-date.

In addition to new developments and disease specific pipeline projects, each report also contains extensive information in tabular format on a company's full product pipeline and products by phase of development with regard to the therapy area.

Full pipeline details, by stage, are provided and include detailed product descriptions, information on partnering activity plus clinical trial intelligence. Each Therapy Area Pipeline Report also provides detail on the top 20 companies with products in the early stage of development and the top 20 companies with products in the late stage of development.

Finally, each report also provides a comparison with other major indications in the disease hub based on Marketed Products vs. Pipeline Products.

Key benefits

* Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline for specific therapy areas.

* Keep track of your competitors and partners by better understanding their product pipeline.

* Monitor a company's research effectiveness by determining pipeline depth and number of products in development by clinical phase for specific disease areas.

* Maintain a critical competitive advantage.

Full Hair Loss Article

Categories: Alopecia, Hair Loss

Scientists in the US are bullish about the discovery of a new hair-loss gene, something that could help the many millions of men with male pattern baldness.

While the gene is specifically linked to a form of hereditary childhood baldness, the researchers from Columbia, Rockefeller and Stanford universities in the US believe that the discovery may in time help those with adult baldness.

The hereditary form, known as hypotrichosis simplex, causes “hair follicle miniaturisation”, says Dr Angela Christiano, professor of dermatology and genetics and development at Columbia. She and colleagues publish their findings this morning in the journal Nature.

The errant gene culprit, APCDD1, was identified by analysing genetic information from several families from Pakistan and Italy affected by hereditary childhood hair loss.

While this occurs in children affected by hypotrichosis simplex, shrinking follicles are also central to male pattern baldness, says Dr Christiano. In both cases the follicles shrink, causing normal thick hair to be replaced by thin fine hair, also known as “peach fuzz”, the authors write.

Dr Christiano points out that while both conditions deliver a similar result, the gene discovery does not fully explain what lies behind male baldness. Yet, the discovery is important for what it might tell us about the onset of thinning hair.

“The identification of this gene underlying hereditary hypotrichosis simplex has afforded us an opportunity to gain insight into the process of hair follicle miniaturisation, which is most commonly observed in male pattern hair loss or androgenetic alopecia,” Dr Christiano says

Full Hair Loss Article

Categories: Hair Loss, Hair Loss Treatment